Research Article
Systemic Lupus Erythematosus, Its Impact on Selected Cardiovascular Risk Factors, and Correlation with Duration of Illness: A Pilot Study
Table 2
Treatment, SLE specific symptoms, serological data, and treatment used in the SLE group.
| | Treatment | Study group n (%) |
| | Corticosteroids | 17 (44.74) | | Azatioprine | 4 (10.52) | | Chloroquine | 17 (44.74) | | Chloroquine with metotrexate | 1 (2.63) | | GCS with chloroquine | 4 (10.52) | | GCS with azatioprine | 2 (5.26) | | Without treatment | 6 (15.79) | | SLE characteristics | | Facial erythema (“butterfly rash”) | 30 (78.95) | | Erythema elsewhere | 25 (65.79) | | Skin hypersensitivity to light | 31 (81.58) | | Oral ulcers | 9 (23.68) | | Synovitis (>2 joints) | 32 (84.21) | | Nonscarring alopecia | 20 (52.63) | | Raynaud symptom | 10 (26.31) | | Serological | | ANAs (+) | 34 (89.47) | | dsDNA | 20 (52.63) | | RNP | 2 (5.26) | | SSA/Ro | 19 (50.00) | | SSB/La | 3 (7.89) | | Sm | 7 (18.42) |
|
|
GCS: corticosteroids; ANAs : antinuclear antibodies; dsDNA : anti-double-strand DNA antibodies; RNP : antiribonucleoprotein antibodies; SSA/Ro : anti-Ro antibodies; SSB/La : anti-La antibodies; Sm : anti-Smith antibodies. Source: own studies.
|
